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A Case of Primary Colon Carcinoma Demonstrated by FDG PET/CT 
Imaging After Detection of a Solitary Brain Metastasis
Soliter Beyin Metastazının Saptanmasından Sonra FDG PET/BT ile Primer Kolon Karsinomu 
Gösterilen Bir Olgu
Abstract
The detection of brain metastases as the initial manifestation of colorectal carcinoma without liver or lung involvement is 
extremely rare. Herein we present a case of a 52-year-old male patient with an unusual presentation of colon cancer, with 
primary lesions demonstrated by fluorine-18-labeled fluorodeoxyglucose (FDG) Positron-emission tomography/computed 
tomography (PET/CT) after detection of a solitary brain metastasis. Brain CT images revealed a brain tumor. Histopathologic 
evaluation indicated metastatic poorly differentiated adenocarcinoma, while his physical examination was normal. The PET/
CT revealed abnormal intense FDG uptake in the right parietal region and in descending colon, with no other abnormal 
FDG uptake elsewhere in the body. The histopathologic diagnosis of the descending colon lesion revealed moderately 
differentiated adenocarcinoma. This case indicates that FDG PET/CT imaging may have a positive impact on the evaluation of 
patients with brain metastasis from an unknown primary. 
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Özet
Karaciğer veya akciğer tutulumu olmaksızın kolorektal karsinomunun ilk klinik bulgusu olarak beyin metastazının görülmesi son 
derece nadirdir. Burada, soliter beyin metastazının saptanmasından sonra, primer lezyonu flor-18-işaretli fluorodeoksiglukoz 
(FDG) Pozitron-emisyon tomografi/bilgisayarlı tomografi (PET/BT) ile gösterilen nadir kolon kanserli 52 yaşında erkek bir olguyu 
sunduk. Beyin BT görüntülerinde, beyin tümörü saptandı. Histopatholojik inceleme metastatik az diferansiye adenokarsinomayı 
gösterdi. Fizik muayene normaldi. PET/BT sağ parietal bölgede ve inen kolonda yoğun FDG tutulumu gösterdi, vücudun başka 
bir yerinde anormal FDG tutulumu izlenmedi. İnen kolondaki lezyonun histopatolojik tanısı orta diferansiye adenokarsinoma 
ile uyumluydu. Bu olgu, FDG PET/BT görüntülemenin primeri bilinmeyen beyin metastazlı hastaların değerlendirilmesinde 
olumlu etkiye sahip olabileceğini gösterdi. 
Anahtar Kelimeler: Pozitron-emisyon tomografi/bilgisayarlı tomografi, beyin tümörleri, kolon kanseri, bilinmeyen primer 
tümörler 
Çıkar Çatışması: Yazarlar bu makale ile ilgili olarak herhangi bir çıkar çatışması bildirmemiştir.
14
Erhamamcı et al. Brain Metastasis from Primary Colon Carcinoma
Introduction 
Approximately 15-20% of patients with colorectal cancer 
(CRC) harbor distant metastases at the time of diagnosis. 
The most common metastatic sites for CRC are the liver, 
lungs and peritoneum. Brain metastases (BM) from CRC is 
rare in comparison to other common malignancies, such as 
lung, breast, and renal carcinoma. Brain metastases occur 
in 1-3% of patients with CRC at the time of diagnosis, and 
in up to 10% of patients during subsequent disease course 
(1,2). Usually, the development of BM is the terminal stage 
of colorectal carcinoma and generally occurs in patients 
with extensive metastatic disease.
The development of new modalities such as fluorine-
18-labeled fluorodeoxyglucose (FDG) positron emission 
tomography combined with computed tomography (PET/CT) 
has contributed to the evaluation of various types of cancer, 
and the benefits of FDG PET/CT for cancer staging are 
well established. Previous studies have reported diagnostic 
contribution of whole-body FDG PET/CT scan in the 
evaluation of patients with unknown primary cancer, and 
suggested early utilization of this method to optimize patient 
diagnosis and management (3,4). FDG PET/CT detects more 
metastatic sites than other modalities and discloses the site 
of the primary tumor in 20-40% of cases (5,6). 
In this report, patient with an unusual presentation of 
colon cancer, with primary lesions demonstrated by FDG 
PET/CT after detection of a solitary BM without any liver 
or lung involvement. This case indicates that FDG PET/CT 
imaging may have a positive impact on the evaluation of 
patients with brain metastasis from an unknown primary. 
Case Report
A 52-year-old male patient, with a clinical history of 
diabetes mellitus, was admitted to the hospital due to left 
hemiparesis. Cranial computed tomography (CT) showed 
a solitary lesion located at the right parietal region. The 
patient underwent craniectomy and excisional biopsy. 
Histopathologic evaluation demonstrated the cerebral lesion 
to be a metastatic poorly differentiated adenocarcinoma. 
His initial work-up included physical examination, laboratory 
and imaging studies. Blood chemistry did not reveal any 
remarkable abnormalities, including tumor markers, such 
as carcinoembryonic antigen (CEA), carbonhydrate antigen 
(CA) 19-9 and CA 15-3. Tumor markers and thorax ve 
abdominal CT failed to identify the primary site. 
The patient was referred to Nuclear Medicine Department 
for FDG PET/CT, in order to localize the primary tumor. FDG 
PET/CT whole body scan (Discovery-STE 8; General Electric 
Medical System, Milwaukee, Wisconsin, USA) was performed 
60 minutes after intravenous injection of 403.3 MBq (10.90 
mCi) of FDG. FDG PET/CT images showed increased metabolic 
activity in the descending colon at the left abdominal region 
and in the right parietal region of the brain (Figure 1). No 
other abnormal FDG uptake was detected elsewhere in the 
body. Colonoscopy was performed and the histopathologic 
examination revealed an adenocarcinoma. The patient 
underwent whole brain radiotherapy (WBRT) for a total dose 
of 30 Gy in 10 fractions. Subsequently, subtotal colectomy 
was performed. Pathologic examination of the resected 
tissue revealed a moderately differentiated adenocarcinoma 
that infiltrated the serosa and pericolonic fat with mucinous 
differentiation in less than 30%. Metastatic adenocarcinoma 
was detected in mesenteric lymph nodes with lymphovascular 
invasion (T3N1M1). The patient was eventually diagnosed 
with stage IV adenocarcinoma of the descending colon 
and was started on systemic chemotherapy. The patient 
underwent only one cure of chemotherapy. He died due to 
systemic complications of the disease at four months after 
the diagnosis of brain metastasis. 
Literature Review and Discussion
Brain metastases are the most common intracranial 
tumors, and occur in about 10-40% of all cancer patients (1,7). 
In the last decade, the detectability of BM has increased owing 
to improvements in radiologic techniques and in survival rates 
due to multimodality therapies that led to an increase in the 
risk of developing BM (8). It is reported that up to one third 
of patients with BM do not have a previous cancer history 
(9). Additionally, in up to 10% of patients, even after a time-
consuming and costly workup, the primary tumor site remains 
unknown (10). At initial presentation, up to 63% of the 
patients have multiple tumors, while 37-50% present with a 
single BM (11). Approximately 80% of lesions are found in the 
cerebrum, 15% in the cerebellum, and 5% in the brain-stem. 
Brain metastases from CRC are rare and usually tend to 
appear in the late course of the disease, coexisting with liver 
or lung metastases in most cases (1,8). The venous drainage 
of the bowel is via the portal system resulting in the liver to be 
the main site for metastases, followed by the lungs. At later 
Figure 1. Maximum intensity projection (A), axial PET (B), fusion (C), 
computed tomography (D), and fusion (E) images showed increased 
metabolic activity in the thickened left descending colon (thin arrows), and 
right parietal lobe (bold arrows). However, no other abnormal FDG uptake 
was observed elsewhere in the body
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stages, tumor cells enter the systemic circulation and spread 
to any organ system. Within these systems, BM are infrequent 
(1,12,13,14). Central nervous system metastases are more 
common in rectal cancer as compared to colon cancer since 
its venous drainage is into the inferior vena cava, therefore 
by-passing the liver, but in such cases lung metastases are 
more frequent (8). In other words, BM that is associated with 
liver or lung metastases are more frequent than isolated BM.
Solitary BM as the initial manifestation of primary 
colon carcinoma without any liver or lung involvement is 
extremely rare, with only few cases reported in the literature 
(12,13,14). In this case report, we present a male patient 
with solitary BM secondary to adenocarcinoma of the 
descending colon without any other organ involvement. 
In patients with BM, detection of the primary tumor 
may optimize treatment planning and improve patient 
outcome. Indeed, some studies have shown that survival 
in patients in whom a primary tumor was eventually 
detected was higher than in patients in whom the primary 
tumor remained undetected (9,10). Additional diagnostic 
procedures that can be used for primary tumor detection 
include a combination of various radiologic, endoscopic, 
and serum tumor marker studies, depending on the 
specific signs and symptoms, histological and laboratory 
abnormalities. However, these tests can be expensive, time-
consuming and invasive. Furthermore, in the majority of 
patients these tests may eventually fail to detect a primary 
tumor (10). Clearly, there is a need for an alternative, 
noninvasive imaging modality with a high diagnostic yield. 
The development of FDG PET/CT has contributed to the 
evaluation of cancer staging and detection of unknown 
primary tumor origins (3,4,5,6). FDG PET/CT can also 
identify additional sites of metastases that can alter the 
patient’s management, which probably improves survival 
time and at the same time can serve as a guide for biopsies, 
as shown in our patient. Many researches have shown that 
FDG PET is a useful tool to locate the primary lesion, both in 
patients with metastases in the head and neck region and 
in patients with extra-cervical metastases (3).
The prognosis of patients with BM from CRC is dismal. 
The median survival after the diagnosis of BM is reported 
as 2.7-8.3 months (2). There is controversy regarding the 
best treatment for patients with BM. Some patients benefit 
from a multidisciplinary management strategy. The main 
treatment modalities for single brain metastases are WBRT, 
surgery and stereotactic radiosurgery (15,16). The patient 
presented herein underwent surgery, WBRT and systemic 
chemotherapy, but unfortunately, he died four months 
after the initial diagnosis of BM. 
In conclusion, we report a rare patient with primary colon 
carcinoma detected by FDG PET/CT following identification 
of a solitary brain metastasis. FDG PET/CT whole body 
imaging is both a noninvasive and a very sensitive 
tomographic whole-body imaging modality, allowing for 
the detection of a primary tumor and complete tumor 
staging all in one single examination, which may contribute 
substantially to selecting appropriate therapeutic methods 
and evaluating prognosis.
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